From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...

Scientists have developed a new chimeric antibody that suppresses malignant cancers in dogs, showing promise for safe and effective treatment of intractable cancers. Similar to our aging society, dogs ...

A retrospective study suggests a high burden of prolonged, mostly low-grade infections in patients with multiple myeloma who receive T-cell-engaging therapies.

Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis PURPOSE: To ...

Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...

This review focuses on patient care tips and practices for the care of patients with B-NHL or MM receiving bispecific antibody therapy.

Antibody engineering enables the generation of novel and diverse antibody constructs. The development of therapeutic antibodies is highly dependent on antibody engineering, whether for the generation ...

Chimeric antigen receptors (CARs) are artificial immunoreceptors that drive T cell-mediated tumor destruction. CAR-modified T cells have demonstrated unprecedented clinical success, leading to six FDA ...

Researchers from Nitrase Therapeutics Inc. recently presented preclinical findings on NTX-101, a murine chimeric antibody designed to specifically bind to nitrated tyrosine on α-synuclein (α-Syn). It ...

In 1975, Georges Köhler and César Milstein, biochemists from the Medical Research Council Laboratory of Molecular Biology, published a paper in Nature about a hybridoma technology that enabled the ...